Total net revenue for full-year 2022 expected to be approximately $164 to $165 million; MACI net revenue for full-year 2022 expected to be approximately $132 million; Burn Care net revenue for full-year 2022 expected to be approximately $32.5 million; Fourth quarter MACI revenue growth expected to be approximately 24% versus prior year; Expect tenth straight quarter with positive adjusted EBITDA and Operating Cash Flow; As of December 31, 2022, the Company had approximately $140 million in cash and investments and no debt.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VCEL:
- Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
- Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
- H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
- Vericel price target raised to $37 from $35 at H.C. Wainwright
- MediWound price target raised to $25 from $6 at Cowen